Core Viewpoint - Duori Pharmaceutical (301075) announced on September 30, 2025, that it received a notification from its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., regarding a potential change in company control, which may lead to a change in the controlling shareholder and actual controller [1] Group 1 - The company is currently in discussions regarding the overall plan for the control change, and no formal agreements have been signed yet [1] - As a result of the ongoing negotiations, the company anticipates that it will not be able to resume trading on October 9, 2025, at market opening [1] - The company has applied to the Shenzhen Stock Exchange for an extension of its stock suspension, which is expected to last no more than three trading days [1]
多瑞医药：筹划控制权变更 股票自10月9日起继续停牌